OEM/ODM Manufacturer Glioblastoma Multiforme - Favipiravir CAS 259793-96-9 T-705 COVID-19 API High Quality – Ruifu

Short Description:

Product Detail

Product Tags

Feedback (2)

We've one of the most innovative manufacturing devices, experienced and qualified engineers and workers, recognized good quality handle systems and also a friendly experienced income team pre/after-sales support for Weight 320.75, Methyl 5-bromo-6-chloronicotinate, Molecular Formula C18H14BrNO3, If you are looking for a good quality, fast delivery, best after service and good price supplier in China for long-term business relationship, we will be your best choice.

OEM/ODM Manufacturer Glioblastoma Multiforme - Favipiravir CAS 259793-96-9 T-705 COVID-19 API High Quality – Ruifu Detail:

Manufacturer with High Purity and Stable Quality
Commercial Supply Favipiravir (CAS: 259793-96-9) and Related Intermediates:
Favipiravir CAS: 259793-96-9
3,6-Dichloropyrazine-2-Carbonitrile CAS: 356783-16-9
3,6-Difluoropyrazine-2-Carbonitrile CAS: 356783-28-3
6-Bromo-3-Hydroxypyrazine-2-Carboxamide CAS: 259793-88-9
3-Hydroxypyrazine-2-Carboxamide CAS: 55321-99-8
2-Aminopropanediamide CAS: 62009-47-6
Diethyl Aminomalonate Hydrochloride CAS: 13433-00-6

Chemical Name	Favipiravir
Synonyms	T-705; 6-Fluoro-3-Hydroxy-2-Pyrazinecarboxamide
CAS Number	259793-96-9
CAT Number	RF-API18
Stock Status	In Stock, Production Scale Up to Hundreds of Kilograms
Molecular Formula	C5H4FN3O2
Molecular Weight	157.1
Brand	Ruifu Chemical

Item	Specifications
Appearance	Off-White Powder
Identification	1) IR 2) HPLC
Melting Point	188.0℃-193.0℃
Related Substances (Area Normalization)	Any Single Impurity: ≤0.10% (HPLC)
Related Substances (Area Normalization)	Total Impurities: ≤1.0% (HPLC)
Purity / Analysis Method	≥99.0% (HPLC)
Moisture (K.F)	≤0.50%
Residue on Ignition	≤0.10%
Heavy Metals	≤20ppm
Residue Solvents
Methanol	≤3000ppm
Ethyl Acetate	≤5000ppm
Isopropanol	≤5000ppm
Acetonitrile	≤410ppm
n-Heptane	≤5000ppm
Test Standard	Enterprise Standard
Usage	Active Pharmaceutical Ingredient (API); Treatment of COVID-19

Package: Bottle, Aluminum foil bag, 25kg/Cardboard drum, or according to customer’s requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.

Favipiravir (T-705) (CAS 259793-96-9) is one of the 5 compounds recommended by WHO for the investigation of treatment of COVID-19.

Favipiravir (T-705) is a selective inhibitor of viral RNA-dependent RNA polymerase with activity against many RNA viruses, influenza viruses, West Nile virus, yellow fever virus, foot-and-mouth disease virus as well as other flaviviruses, arenaviruses, bunyaviruses and alphaviruses. Favipiravir is a broad-spectrum antiviral drug that was cleared by the Drugs Controller General of India (DCGI) last week for “emergency restricted” use among Covid-19 patients. Favipiravir was originally developed in the late 1990s by a company that was later purchased by the Japanese firm Fujifilm as part of its transition from the photo business to healthcare. After being tested against a range of viruses, the drug was approved in Japan in 2014 for emergency use against flu epidemics or to treat new strains of influenza.

Product detail pictures:

Related Product Guide:

With a sound business credit, excellent after-sales service and modern manufacturing facilities, we have earned an excellent reputation among our customers across the world for OEM/ODM Manufacturer Glioblastoma Multiforme - Favipiravir CAS 259793-96-9 T-705 COVID-19 API High Quality – Ruifu , The product will supply to all over the world, such as: Ethiopia, Gambia, Paris, Due to good quality and reasonable prices, our products have been exported to more than 10 countries and regions. We are looking forward to cooperating with all customers from at home and abroad. Moreover, customer satisfaction is our eternal pursuit.